Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-17
2005-05-17
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S016700, C514S015800, C514S018700, C424S070210
Reexamination Certificate
active
06894028
ABSTRACT:
The present invention is directed to a prevention and treatment for dermatological disorders. One aspect of this invention involves a dermatological treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment and prevention of dermatological disorders. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above.
REFERENCES:
patent: 5028592 (1991-07-01), Lipton
patent: 5157023 (1992-10-01), Lipton
patent: 5739111 (1998-04-01), Mahe
patent: 6001812 (1999-12-01), Mahe
patent: 0972 522 (2000-01-01), None
patent: 2784028 (2000-04-01), None
patent: WO 9301211 (1993-01-01), None
patent: WO97/10838 (1997-03-01), None
patent: WO99/58101 (1999-11-01), None
patent: PCTUS00/07846 (2000-03-01), None
patent: WO0042856 (2000-07-01), None
Cutluli et al. 2000, Antimicrobial Effects of alpha-MSH peptides, Journal of Leukocyte Biology, vol. 67, No. 2 pp. 233-239.*
Getting, et al., POMC Gene-Derived Peptides Activate Melanocortin Type 3 Receptor on Murine Macrophages, Suppress Cytokine Release, and Inhibit Neutrophil Migration in Acute Experimental Inflammation, J. Immunol., vol. 162, No. 12, pgs. 7446-7453, (1999).
Harris, et al., Alpha-melanocyte stimulating hormone (a-MSH) and melanin-concentrating hormone (MCH) stimulate phagocytosis by head kidney leucocytes of rainbow trout (Oncorhynchus mykiss) in vitro, Fish & Shellfish Immunol., vol. 8, 8:631-638 (1998).
Huang, et al., Role of central melanocortins in endotoxin-induced anorexia, Am. J. Physio (Regulatory, Integrative & Comparative Physiology, vol. 276, No. 3, pgs. R864-R871 (1999).
Lipton, et al., Mechanisms of antiinflammatory action of the neuro immunonomodulatory peptide alpha-MSH, Annals of the N.Y. Acad. Sci., vol. 840, pgs. 373-380 (1998).
Weiss, et al., Corticotropin-peptide regulation of intracellular cyclic-AMP production in cortical neurons in primary culture, J. Neurochem. vol. 45, No. 3, pgs. 869-874 (1985).
Airaghi, L., et al., “Elevated concentrations of plasma α-MSH are associated with reduced disease progression in HIV-infected patients,” J. Lab. Clin. Med. 133(3) 309-315 (1999).
Airaghi L, Lettino M, Manfredi MG, Lipton JM, Catania A. Endogenous cytokine antagonists during myocardial ischemica and thrombolytic therapy. Am. Heart J. 130: 204-211, 1995.
Airaghi L. Garofalo L. Cutuli MG. Delgado R. Carlin A. Demitri MT. Badalamenti S. Graziani G. Lipton JM. Catania A. Plasma concentrations of α-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis. Nephrology Dialysis Transplantation 15:1212-1216, 2000.
Baker, M., et al., “The Relationship between Interleukin-6 and Simplex Virus Type-1: Implications for Behavior and Immunopathology,”Brain Behav. Immun.13(3):201-11 (1999).
Baker, et al., “Principles of Ambulatory Medicine,”Williams and Wilkins(1982).
Barcellini, W., et al., “Inhibitory Influences of α-MSH peptides on HIV-1 expression in Monocytic cells,” 12thWorld AIDS Conference Geneva, Abstract No. 60685, Jun. 28-Jul. 3, 1998.
Barcellini W, La Maestra L, Clerici G, Garofalo L, Brini AT, Lipton JM, Catania A. α-MSH peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. Journal of Leukocyte Biology 68:693-699, 2000.
Bhattacharya A., et al., “Effect of Cyclic AMP on RNA and Protein Synthesis inCandida albicans,” Biochem, Biophysics. Res. Commun.,77: 1438-44 (1977).
Bickers, D., Sun-Induced Disorders,Emergency Medicine Clinicis of North America,3(4):659-663, 660 (1985).
Capsoni, F., et al., “Effect of Corticosteriods on Neutrophil Function: Inhibition of Antibody-dependent Cell-Mediated Cytotoxicity (ADCC),”J. Immunopharmacol217-30 (1983).
Cartledge, J.D., et al., “Clinically Significant Azole-Cross-Resistance in Candida Isolates from HIV-Positive Patients with Oral Candidosis,”AIDS11:1839-44 (1997).
Catania, A., et al., “α-Melanocyte Stimulating Hormone in the Modulation of Host Reactions,”Endocr. Rev.14, 564-576 (1993).
Catania, A., et al., “Melanocortin Peptides Inhibit Production of Proinflammatory Cytokines in Blood of HIV-Infected Patients,”Peptides,19(6): 1099-1104 (1998).
Catania, A., et al., “The Neuropeptide α-MSH in HIV Infection and Other Conditions in Humans,”Ann. N.Y. Acad. Sci.840: 848-856 (1988).
Catania, A.; et. al., “The Neuropeptide α-MSH has Specific Receptors on Neutrophils and Reduces Chemotaxis in Vitro,”Peptides17, 675-679 (1996).
Catania A, Airaghi L, Lipton JM. α-MSH in normal human physiology and disease states. Trends Endocrinol. Metab. 11:304-308, 2000.
Catania A, Delgado R, Airaghi L, Cutuli M, Garofalo L, Carlin A, Demitri MT, Lipton JM. α-MSH in systemic inflammation: central and peripheral actions. Annals of the New York Academy of Sciences, 885:183-187, 1999.
Catania A, Grazia M, Manfredia MG, Airaghi L, Ceriani G, Gandino A, Lipton JM. Cytokine antagonists in infectious and inflammatory disorders. Annals of the New York Academy of Sciences 741: 149-161, 1994.
Catania A. Lipton JM. α-melanocyte-stimulating horomone peptides in host responses: from basic evidence to human research. Annals of the New York Academy of Sciences 680: 412-423, 1993.
Catania A, Cutuli M, Garofalo L, Airaghi L, Valenza F, Lipton JM, Gattinoni L. Plasma concentrations and anti-L-cytokine effects of αmelanocyte stimulating hormone in septic patients. Crit. Care Med. 28: 1403-1407, 2000.
Catania A, Airaghi L, Motta P, Manfredi MG, Annoni G, Pettenati C, Brambilla F and Lipton JM. Cytokine antagonists in aged subjects and their relation with cellular immunity. Journal of Gerontology: Biological Sciences 52A: B93-97, 1997.
Catania A, Manfredi MG, Airaghi L, Vivirito MC, Capetti A, Milazzo, F, Lipton JM and Zanussi C. Plasma concentration of cytokine antagonists in patients with HIV infection. Neuroimmunomodulation 1: 42-49, 1994.
Catania A, Airaghi L, Manfredi MG, Vivirito MC, Milazzo F, Lipton JM, Zanussi C: Proopiomelanocortin-derived peptides and cytokines: relations in patients with acquired immunodeficiency syndrome. Clinical Immunology and Immunopathology 66: 73-79, 1993.
Cavello, J. and Deleo, V., Sunburn,Dermatologic Clinics,4(2): 181-187, 181 (1986).
Ceriani, G., et. al., “Central Neurogenic Antiinflammatory Action of α-MSH: Modulation of Peripheral Inflammation Induced by Cytokines and other Mediators of Inflammation,”Neuroendocrinology,59:138-143 (1994).
Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation 1:28-32, 1994.
Chiao H, Foster S, Thomas R, Lipton J, and Star RA. α-MSH reduces endotoxin-induced liver inflammation. J. Clin. Invest. 97:2038-2044, 1996.
Csato, M. et al., “Enhancement of Candida albicans killing activity of separted human epidermal cells by alpha-melanocyte stimulating hormone,” British Journal of Dermatology, 121(1) 145-147 (1989).
Cutuli, M. et al., “Antimicrobial effects of α-MSH peptides,” Journal of Leukocyte Biology 67:233-239 (2000).
Deeter, L.B., et al., Antipyretic Properties of Centrally Administered α-MSH Fragments in the Rabbit,Peptides(, 1285-1288 (1989).
Delgado, R., et al., “Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia,”Journal of Leukocyte Biology,63: 740-745 (1998).
Domk-Optiz, I., et al., “Stimulation of Macrophages by Endotoxin Results in the Reactivation of a Persistent Herpes Simplex Virus Infection,”Scand J. Immunol.32(2):69-75 (1990).
Eberle, A. and Schwyzer, R., Hormone-Receptor Interactio
Catania Anna P.
Lipton James M.
Chism B. Dell
Perkins Coie LLP
Tate Christopher R.
Zengen, Inc.
LandOfFree
Use of KPV tripeptide for dermatological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of KPV tripeptide for dermatological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of KPV tripeptide for dermatological disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3443649